Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules

Journal of Neuroimmunology

Volumn 133, Issue 1-2, 2002, Pages 151-159

  Fainardi, Enrico ^a   Granieri, Enrico ^a   Tola, Maria Rosaria ^a   Melchiorri, Loredana ^a   Vaghi, Luca ^a   Rizzo, Roberta ^a   Castellazzi, Massimiliano ^a   Ceruti, Stefano ^b   Paolino, Ezio ^a   Baricordi, Olavio Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Cerebrospinal fluid; Intrathecal synthesis; Multiple sclerosis; sHLA I

Indexed keywords

HLA ANTIGEN CLASS 1;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BRAIN INJURY; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMYELINATION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; IMMUNOREGULATION; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE; PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSING REMITTING MULTIPLE SCLEROSIS; RETROSPECTIVE STUDY; SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS;

ADULT; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 0036890043     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00348-X     Document Type: Article

References (36)

1. Alvarez-Cermeño J.C., Echevarria J.M., Villar L.M., Lazaro I., Bootello A., Gonzales-Porque P. Soluble class I antigens in serum and CSF of patients with varicella-zoster virus meningitis. J. Neurol. Neurosurg. Psychiatry. 52:1989;1194-1196.
2. Alvarez-Cermeño J.C., Casado C., Villar L.M., Ferreria A., Varala J.M., Dominguez M., Bootello A., Najera L., Gonzales-Porque P. Soluble class I antigens (sHLA) in CSF and serum of patients with HIV infection. Acta Neurol. Scand. 82:1990;14-16.
3. Alvarez-Cermeño J.C., Villar L.M., Nocito M., Bootello A., Gonzales-Porque P. Intrathecal synthesis of soluble HLA class I antigens in multiple sclerosis. J. Neuroimmunol. 36:1992;77-79.
4. Alvarez-Cermeño J.C., Brieva J.A., Villar L.M., Roldan E., Bootello A., Gonzales-Porque P. Soluble HLA class I antigen secretion by peripheral blood lymphocytes in multiple sclerosis. Eur. Neurol. 33:1993;229-231.
5. Bjorkman P.J., Saper M.A., Samraoui B., Bennett W.S., Strominger J.L., Wiley D.C. Structure of the human class I histocompatibility antigen HLA-A2. Nature. 329:1987;506-512.
6. Carosella E., Moreau P., Aractingi S., Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol. 22:2001;553-555.
7. Filaci G., Contini P., Bronci S., Gazzola P., Lanza L., Scudeletti M., Indiveri F., Mancardi L., Puppo F. Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. Hum. Immunol. 54:1997;54-62.
8. Giovannoni G., Kieseier B., Hartung H.P. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 64(Suppl. 1):1998;S31-S36.
9. Grumet F.C., Buelow R., Grosse-Wilde H., Kubens B., Garovoy M., Pouletty P. Report of the Second International Soluble HLA (sHLA) Workshop. Hum. Immunol. 40:1994;153-165.
10. Hawkins C.P., Munro P.M.G., MacKenzie F., Kesselring J., Tofts P.S., Du Boulay P.G.H., Landon D.N., McDonald W.I. Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DPTA and protein markers. Brain. 113:1990;365-378.
11. Inostroza J., Munoz P., Espinoza R., Millaqueo L., Diaz P., Leiva L., Sorensen R. Quantitation of soluble HLA class I heterodimers and beta 2-microglobulin in patients with active pulmonary tubercolosis. Hum. Immunol. 40:1994;179-184.
12. Kermode A.G., Thompson A.J., Tofts P., MacManus D.G., Kendall B.E., Kingsley D.P.E., Moseley I.F., Rudge P., McDonald W.I. Breakdown of blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain. 113:1990;1477-1489.
13. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability scale (EDSS). Neurology. 33:1983;1444-1452.
14. Laman J.D., Thompson E.J., Kappos L. Balancing the Th1/Th2 concept in multiple sclerosis. Immunol. Today. 19:1998;489-490.
15. Lublin D.F., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
16. Lucchinetti C., Brück W., Prisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for pathogenesis of demyelination. Ann. Neurol. 47:2000;707-717.
17. Lucchinetti C., Brück W., Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr. Opin. Neurol. 14:2001;259-269.
18. Martino G., Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 12:1999;309-321.
19. Martino G., Furlan R., Brambilla E., Bergami A., Ruffini F., Gironi M., Poliani P.L., Grimaldi L.M.E. Cytokines and immunity in multiple sclerosis: the dual signal hypothesis. J. Neuroimmunol. 109:2000;3-9.
20. Mc Donald J.C., Adamashvili E. Soluble HLA: a review of literature. Hum. Immunol. 59:1998;387-403.
21. Miller D.H., Barkhof F., Nauta J.J.P. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain. 116:1993;1077-1094.
22. Neumann H., Cavalie A., Jenne D.E., Wekerle H. Induction of MHC class I genes in neurons. Science. 269:1995;549-552.
23. Neumann H., Schmidt H., Cavalie A., Jenne D., Wekerle H. Major histocompatibility complex (MHC) class I gene expression in a single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J. Exp. Med. 185:1997;305-316.
24. Ott M., Seidl C., Westhoff U., Stecker K., Seifred E., Fischer P.A., Grosse-Wilde H. Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tissue Antigens. 51:1998;301-304.
25. Poser C.M., Paty D.W., Scheimberger L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for MS: guidelines for research protocols. Ann. Neurol. 13:1983;227-231.
26. Puppo F., Scudeletti M., Indiveri F., Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol. Today. 16:1995;124-127.
27. Puppo F., Contini P., Ghio M., Brenci S., Scudelletti M., Filaci G., Ferrone S., Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8 (+) Fas (CD95) (+) T lymphocytes. Int. Immunol. 12:2000;195-203.
28. Salden H.J.M., Bas B.M., Hermas J.T., Janson P.C. Analytical performance of the three commercially available nephelometers compared quantifying protein in serum and cerebrospinal fluid. Clin. Chem. 34:1988;1594-1596.
29. Steinman L. Multiple sclerosis: a coordinate immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
30. Thompson A.J., Polman C.H., Miller D.H., Mc Donald W.I., Brochet B., Filippi M., Montalban X., De Sa J. Primary progressive multiple sclerosis. Brain. 120:1997;1085-1096.
31. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders: I. Establishment of reference value. Scand. J. Clin. Lab. Invest. 37:1977;385-390.
32. Traugott U. Multiple sclerosis: relevance of class I and class II MHC expressing cells to lesion development. J. Neuroimmunol. 16:1987;283-302.
33. Wekerle H., Lassmann H. Immunology of multiple sclerosis. Compston A., Ebers G., Lassmann H., McDonald I., Matthews B., Wekerle H. McAlpine's Multiple Sclerosis. 3rd ed. 1998;379-407 Churchill Livingstone, London.
34. Xiao B.G., Link H. Immune regulation within the central nervous system. J. Neurol. Sci. 157:1998;1-12.
35. Zavazava N., Kronke M. Soluble HLA class I antigens induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat. Med. 2:1996;1005-1010.
36. Zavazava N., Hausmann R., Muller-Rucholtz W. Inhibition of anti HLA-B7 alloreactive CTL by affinity purified soluble HLA. Transplantation. 51:1991;838-842.